---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019363"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T20:48:17.846569+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Samsung BioLogics terminates MSA with CytoDyn effective Jan 5, 2024; company has sufficient leronlimab for trials

## Summary
- Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.
- Agreement from April 2019 covered tech transfer, manufacturing, vial filling, and supply for leronlimab.
- Samsung paused manufacturing for all unfulfilled commitments in January 2022.
- CytoDyn states it holds sufficient leronlimab for short-term prospective clinical trials.
- Company plans to continue resolving outstanding issues including breach notice, payment schedule, and extended manufacturing postponement.

## SEC filing metadata
- accession: 0001558370-23-019363
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/0001558370-23-019363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/cydy-20231121x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019363
- JSON: https://secwatch.observer/filing/0001558370-23-019363.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019363.txt

## Key facts
- Material Agreements
  CytoDyn Inc. terminated Master Services Agreement with Samsung BioLogics Co., Ltd. (effective 2023-11-21).
  - Action: termination
  - Agreement: supply
  - Counterparty: Samsung BioLogics Co., Ltd.
  - Effective: 2023-11-21
  source text: On November 21, 2023, Samsung BioLogics Co., Ltd. (“Samsung”), informed CytoDyn Inc., a Delaware corporation (the “Company”), of Samsung’s intent to terminate, effective January 5, 2024, the Master Services Agreement (the “Agreement”) entered into between Samsung and the Company in April 2019.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/0001558370-23-019363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.